WinstonWınston
Back
Perrigo Company logo

Perrigo Company

PRGO
23
Drug Manufacturers - Specialty & Generic · Healthcare
Also trades as: 0Y5E.L
Winston Score
23
Winston is worried
Weak fundamentals across most pillars.
Data as of Aug 23, 2026 · filings through Jun 27, 2026
How the score breaks down
Quality
Mixed
Growth
Weak
Cash Flow
Weak
Stability
Good
Valuation
Data not available
Dividends
Good

Winston Score History

The full picture

Perrigo is a company that makes store-brand, over-the-counter medicines and health products. Think of the generic pain relievers, allergy pills, cough syrups, and baby formula you see at Walmart, CVS, or Target with the store's own label — Perrigo likely made them. The company sells mostly to large retailers and drugstore chains, who then sell the products under their own brand names.

Perrigo earns money by manufacturing these products at scale and selling them to retailers at a lower price than name-brand alternatives. It operates mainly in North America and Europe, with a market cap of about $1.4 billion, making it a mid-sized player in the generic consumer health space. Its competitive edge comes from long-standing retailer relationships and the complexity of getting FDA approval for generic products, which keeps some competitors out. However, the company carries significant debt and its low operating margin of roughly 6% leaves little room for error if sales slow or costs rise.

Politician Trades

4 trades / 12mo

1 Congressional buy and 3 sells on PRGO in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-3.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+988.2% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

0.5%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$400M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Perrigo Company's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
30.7%
Modest — 30.7% gross margin
Profit after running costs
Operating Margin
2.3%
Thin — 2.3% operating margin
Return on the money invested
ROCE
8.5%
Below par — 8.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-4.2%
Shrinking sales (-4.2% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
2.9%
Thin free cash flow (2.9%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.00
Conservative — low debt load (0.00)
Covers its interest
Interest Cover
1.32x
Dangerous — barely covers interest (1.3x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
11.47%
no trend
Healthy income — 11.47% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record
Dividend Growth
+1.2%
no trend
Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial